Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Daily News

A Simple Nudge Moves the Needle on Statin Prescribing

Michael O'Riordan

December 02, 2022

News Conference News AHA 2021

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

Michael O'Riordan

November 19, 2021

News Features

Hydroxychloroquine: No Help, Clear Harm in COVID-19 RCT and Cohort Studies

Shelley Wood

May 20, 2020

News Daily News

FDA Expands TAVR Indication to Low-Risk Patients

Michael O'Riordan

August 16, 2019

News Daily News

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

L.A. McKeown

March 15, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2019

Caitlin E. Cox

January 31, 2019

News Conference News ISET 2019

Paclitaxel in PAD: What to Tell Patients While the Numbers Are Crunched

Caitlin E. Cox

January 28, 2019

News Daily News

FDA Alerts Doctors to Potential Late Risks With Paclitaxel-Coated Balloons and Stents in PAD

Michael O'Riordan

January 17, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2017

Shelley Wood

September 30, 2017

News Daily News

No More Absorb BVS: Abbott Puts a Stop to Sales

Caitlin E. Cox

September 08, 2017

News Features

Catheter Kerfuffle: How Concerning Is Off-Label Use in Stroke Interventions?

Todd Neale

June 21, 2017

News Features

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

Michael O'Riordan

May 08, 2017

News Daily News

Absorb BVS Recalled in Australia From All Centers Not Studying Device

Shelley Wood

May 03, 2017

News Daily News

Under Surveillance: Ballooning Numbers, Better Survival, Lower-Risk Patients in Latest TVT Registry Data

L.A. McKeown

December 13, 2016

News Daily News

USPSTF: Not Enough Evidence to Recommend Routine Lipid Screening in Children and Adolescents

Michael O'Riordan

August 09, 2016

News Daily News

FDA: No More Chances for Embattled Coagulation Monitoring System

Todd Neale

July 13, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

Advertisement

A Simple Nudge Moves the Needle on Statin Prescribing

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

Hydroxychloroquine: No Help, Clear Harm in COVID-19 RCT and Cohort Studies

FDA Expands TAVR Indication to Low-Risk Patients

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

TCTMD’s Top 10 Most Popular Stories for January 2019

Paclitaxel in PAD: What to Tell Patients While the Numbers Are Crunched

FDA Alerts Doctors to Potential Late Risks With Paclitaxel-Coated Balloons and Stents in PAD

TCTMD’s Top 10 Most Popular Stories for September 2017

No More Absorb BVS: Abbott Puts a Stop to Sales

Catheter Kerfuffle: How Concerning Is Off-Label Use in Stroke Interventions?

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

Absorb BVS Recalled in Australia From All Centers Not Studying Device

Under Surveillance: Ballooning Numbers, Better Survival, Lower-Risk Patients in Latest TVT Registry Data

USPSTF: Not Enough Evidence to Recommend Routine Lipid Screening in Children and Adolescents

FDA: No More Chances for Embattled Coagulation Monitoring System

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content